Skip to main content
C

Celestra Inc. — Investor Relations & Filings

Ticker · 352770 ISIN · KR7352770002 KO Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 378 across all filing types
Latest filing 2025-03-06 Declaration of Voting R…
Country KR South Korea
Listing KO 352770

About Celestra Inc.

https://celestrahealth.com/

Celestra Inc. develops and commercializes digital biomarkers for monitoring neurological conditions. The company's core product is the Celestra Health platform, an FDA-designated Class II medical device that provides quantitative gait analysis for patients in their natural environment. The platform utilizes wearable smart insoles equipped with gyroscopes, accelerometers, and pressure sensors to collect movement data. This data is processed by a cloud-based system using advanced machine learning algorithms to measure over 200 aspects of a patient's gait. The system is designed to detect subtle changes in disease progression for conditions such as Multiple Sclerosis and Parkinson’s Disease earlier than traditional clinical assessments. It offers laboratory-grade accuracy, providing clinicians with actionable insights through a proprietary composite index and enabling pharmaceutical firms to assess drug therapy effectiveness more efficiently.

Recent filings

Filing Released Lang Actions
임시주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is an official announcement of the results of an Extraordinary General Meeting (EGM) for Clinomics, dated 2025-03-06. It lists the resolutions passed (amendment of articles of association and capital reduction). According to the filing definitions, the category 'Declaration of Voting Results & Voting Rights Announcements' (DVA) is specifically for official results from shareholder votes at any general meeting.
2025-03-06 Korean
상호변경안내
Regulatory Filings Classification · 1% confidence The document is a short, formal announcement regarding a change of company name (from Clinomics Inc. to Celestra Inc.) following a shareholder meeting. Since it does not fit into specific categories like financial reports, director dealings, or dividend notices, and serves as a general corporate regulatory announcement, it is classified as a Regulatory Filing (RNS).
2025-03-06 Korean
교환사채(해외교환사채포함)발행후만기전사채취득
Capital/Financing Update Classification · 1% confidence The document is a regulatory filing from a Korean company (Clinomics) detailing the acquisition of exchangeable bonds before maturity. It specifies the bond details, acquisition amount, reason for acquisition (mutual agreement), and the method of disposal (cancellation). This falls under capital structure changes and financing updates, specifically related to debt instruments. Given the specific nature of the filing regarding bond acquisition/redemption, it fits best under the 'CAP' (Capital/Financing Update) category.
2025-02-27 Korean
조회공시요구(현저한시황변동)에대한답변(미확정)
Regulatory Filings Classification · 1% confidence The document is a formal response to a 'Request for Disclosure' (조회공시요구) from the Korea Exchange regarding significant market fluctuations. It addresses specific corporate activities such as an upcoming extraordinary general meeting, potential asset sales for financial restructuring, and a planned convertible bond issuance. Since this is a regulatory response to a market inquiry and does not fit into specific categories like M&A or financial reports, it is classified as a general regulatory filing.
2025-02-21 Korean
조회공시요구(현저한시황변동)
Regulatory Filings Classification · 1% confidence The document is a formal request from a regulatory body (exchange) to the company (Clinomics) regarding 'significant market fluctuations' (현저한 시황변동). This is a standard regulatory inquiry requiring a response by a specific deadline. Since it is a regulatory announcement that does not fit into specific categories like earnings or dividends, it falls under the general regulatory filings category.
2025-02-20 Korean
회생절차개시신청(종속회사의주요경영사항)
Legal Proceedings Report Classification · 1% confidence The document is a regulatory filing from Clinomics regarding a subsidiary's (CoNF) application for rehabilitation proceedings (bankruptcy/insolvency protection). This is a significant legal and financial event that does not fit into standard financial reporting categories like 10-K or IR, nor is it a simple announcement of a report. It is a specific regulatory disclosure of a material event, which falls under the 'Regulatory Filings' category.
2025-02-14 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.